Pharmacogenomics research is yielding molecular diagnostic tools that can be used to optimize the selection of medications and their doses for individual patients. Given the narrow therapeutic index of most anticancer agents and the serious consequences of undertreatment, cancer chemotherapy is a compelling therapeutic area for translation of pharmacogenomics to the clinic. This review addresses how inherited (germline) and acquired (somatic) sources of genome variability can alter the toxicity or efficacy of cancer chemotherapy.



Titolo: Cancer Pharmacogenomics
Autori: 
STOCCO, GABRIELE
mostra contributor esterni 
Data di pubblicazione: 2011
Rivista: 
CLINICAL PHARMACOLOGY & THERAPEUTICS  
Abstract: Pharmacogenomics research is yielding molecular diagnostic tools that can be used to optimize the selection of medications and their doses for individual patients. Given the narrow therapeutic index of most anticancer agents and the serious consequences of undertreatment, cancer chemotherapy is a compelling therapeutic area for translation of pharmacogenomics to the clinic. This review addresses how inherited (germline) and acquired (somatic) sources of genome variability can alter the toxicity or efficacy of cancer chemotherapy.
Handle: http://hdl.handle.net/11368/2692209
Digital Object Identifier (DOI): http://dx.doi.org/10.1038/clpt.2011.126
Appare nelle tipologie:1.1 Articolo in Rivista

File in questo prodotto:
Non ci sono file associati a questo prodotto.
Utilizza questo identificativo per citare o creare un link a questo documento:
http://hdl.handle.net/11368/2692209
  • Citazioni
  • ND

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
 
 
 
©2014 University of Trieste dove siamo Privacy
Piazzale Europa,1 34127 Trieste, Italia - Tel. +39 040.558.7111 - P.IVA 00211830328 - C.F. 80013890324 - P.E.C.: ateneo@pec.units.it
 Copyright © 2020